metastatic nasopharyngeal carcinoma
Conditions
Interventions
Experimental group:S1 maintenance therapy
Sponsors
The fourth affiliated hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Aged 18-65 years. 2) Histopathological diagnosis as nasopharyngeal squamous cell carcinoma; 3) Distant metastasis after comprehensive treatment; 4) Patients benefited from the gemcitabine combined cisplatin chemotherapy (CR+PR+SD) ; 5) KPS score>=70; 6) Expected lifetime> 6 months, with follow-up conditions; 7) Without serious heart and lung diseases; 8) Satisfy the following clinical laboratory standards: ANC>=1.5*10^9/L, PLT>=70*10^9/L, liver and kidney function being 1.5 times of the upper limit of normal value; 9) Have signed informed conset.
Exclusion criteria
Exclusion criteria: 1) Cognitive dysfunction; 2) Patients combined other malignant tumor; 3) Chemotherapy contraindications: serious bone marrow dysfunction, bleeding tendency,active infection, within 6 months after myocardial infarction, symptomatic heart disease (unstable angina,congestive heart failure or uncontrolled arrhythmias),immunosuppressive therapy, etc; 4) Women without using contraception during pregnancy and lactation,or fertility; 5) Drug abuse and alcohol addiction; 6) Patients having the allergic reaction for any drugs in the study; 7) Without follow-up conditions; 8) Inappropriate patients being considered by other researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;Disease remission rate;quality of life; | — |
Countries
China
Contacts
Public ContactHuang Haixin
Outcome results
None listed